



# TITAN BIOTECH LTD.



AN ISO 9001:2008 CERTIFIED COMPANY

Office : 903-909, 9th Floor, Bigjos Tower, Netaji Subash Place, Delhi-110034, India  
Tel. : 011-27355742, 71239900 | Fax : +91-11-47619811 | CIN: L74999RJ1992PLC013387

To,  
Corporate Services Department,  
Bombay Stock Exchange Limited,  
Phiroze Jeejeebhoy Tower,  
Dalal Street,  
Mumbai-400001

Date: 13/11/2019

**SUB: OUTCOME OF BOARD MEETING FOR THE APPROVAL OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTH ENDED 30<sup>th</sup> SEPTEMBER, 2019**

Dear Sir/Ma'am,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors, at its meeting held today i.e. **Wednesday 13<sup>th</sup> September, 2019**, at the Corporate Office of the Company at **903-909, 9th Floor, Bigjos Tower, Netaji Subhash place, Delhi-110034**, have approved the Standalone and Consolidated Unaudited Financial Results for the quarter and six month ended 30<sup>th</sup> September, 2019.

In terms of the Provisions of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the following:

- ☐ Unaudited Financial Results for the quarter and six month ended 30<sup>th</sup> September, 2019
- ☐ Limited Review Report for the quarter and six month ended 30<sup>th</sup> September, 2019.

The meeting of Board of Directors commenced at 03:00 P.M. and concluded at 03:30 P.M.

The above information will be available on the website of the company i.e <https://titanbiotechltd.com>  
This is for your kind information and record please.

Thanking You,  
For Titan Biotech Limited

  
**Charanjit Singh**  
Company Secretary  
M.No A12726





# Sunita Agrawal & Co.

(Chartered Accountants)

## Independent Auditor's Limited Review Report

To the Board of Directors of TITAN BIOTECH LIMITED

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **TITAN BIOTECH LIMITED** (the "Company") for the quarter and six months ended **30<sup>th</sup> Sept, 2019** (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Regulation") as amended, read with SEBI Circular No. CIR/CFD/CMDI/44/2019 dated March 29, 2019 (the "Circular").
2. This Statement, which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Sunita Agrawal & Co

Chartered Accountants

ICAI FRN- 515225C

*Sunita*  
(CA Sunita Agrawal)

Partner

Membership No.095196

UDIN-19095196AAAAFE5260



Delhi, Nov 13, 2019

A-160, Upper Lobby Level,  
Boulevard, Crown Plaza, Plot No. 13B,  
Mayur Vihar Phase-1, Delhi-110092  
Ph. : 011-49868379

1/35A, Lalita Park,  
Near Gurudwara, Laxmi Nagar,  
Delhi-110092  
Ph. : 011-22455133

10, Giriraj Colony, Inside Fort  
Bharatpur (Rajasthan)-321001  
Ph. : 05644-225679  
M : 9899567391

103-2B, Panorma Patliputra  
CHS Oshiwara, Jogeshwari West  
Mumbai (Maharashtra)-400102  
M : 08898080517

E-mail : sunitaca\_97@yahoo.com, sac.icai@gmail.com

Web. : [www.consultants.tax](http://www.consultants.tax)



# Sunita Agrawal & Co.


(Chartered Accountants)

## Independent Auditor's Limited Review Report

### To the Board of Directors of TITAN BIOTECH LIMITED

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **TITAN BIOTECH LIMITED** ("the Holding Company") and its subsidiary (the Holding Company and its subsidiary together referred to as "the Group") for the Quarter and Six months ended **30<sup>th</sup> Sept, 2019** ("the Statement") being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended read with SEBI Circular No. CIR/CFD/CMDI/44/2019 dated March 29, 2019 ('the Circular'). Attention is drawn to the fact that the consolidated figures for the corresponding quarter and six months ended 30<sup>th</sup> Sept, 2018 as reported in these unaudited consolidated financial results have been regrouped and approved by the Holding Company's Board of Directors but have not been subjected to review.
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Holding Company personnel and analytical procedures applied to group financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. The Statement includes results of the Holding Company- Titan Biotech Limited and subsidiary Company - Peptech Biosciences Limited.
5. The accompanying unaudited consolidated financial results includes unaudited interim financial results and other unaudited financial information in respect of its subsidiary which have been approved and furnished to us by the Company's management. Our conclusion on the Statement is not modified in respect of the above matter.
6. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Sunita Agrawal & Co  
Chartered Accountants  
ICAI FRN- 515225C

  
(CA Sunita Agrawal)

Partner

Membership No.095196

UDIN- 19095196AAAAFE5260

Delhi, Nov 13, 2019





**TITAN BIOTECH LIMITED**

Regd. Office :- A-902 A, RICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Fax No. +91-11-47619811 Email : hrd@titanbiotechltd.com www.titanbiotechltd.com CIN : L74999RJ1992PLC013387

**STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30TH SEPT. 2019**

(Rs. IN LAKHS) except for EPS

Sr. No	PARTICULARS	STANDALONE					
		QUARTER ENDED			SIX MONTHS ENDED		YEAR ENDED
		30.09.2019	30.06.2019	30.09.2018	30.09.2019	30.09.2018	31.03.2019
		UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
1	<b>INCOME</b>						
	Revenue from operations	1,586.26	1,746.33	1,496.16	3,332.59	2,939.62	5,824.04
	Other Income	38.51	9.05	12.14	47.56	30.12	65.14
	<b>Total Income</b>	<b>1,624.78</b>	<b>1,755.38</b>	<b>1,508.30</b>	<b>3,380.16</b>	<b>2,969.74</b>	<b>5,889.18</b>
2	<b>EXPENSES</b>						
	Cost of Materials Consumed	804.88	993.56	823.30	1,798.44	1,641.07	3,449.55
	Changes in inventories of Finished Goods, Stock-in-Trade and Work-in-Progress	15.65	11.70	(35.42)	27.35	-113.92	(388.33)
	Employee Benefit Expenses	234.94	223.37	210.66	458.31	410.72	848.79
	Finance Costs	44.49	51.11	53.26	95.60	98.64	203.70
	Depreciation and Amortization Expenses	43.67	43.20	27.98	86.87	87.30	167.71
	Other Expenses	295.58	262.11	306.74	557.69	619.50	1,172.17
	<b>Total Expenses</b>	<b>1,439.21</b>	<b>1,585.05</b>	<b>1,386.52</b>	<b>3,024.26</b>	<b>2,743.31</b>	<b>5,453.60</b>
3	Profit/(loss) before exceptional items and tax (1-2)	185.57	170.33	121.78	355.90	226.43	435.58
4	Exceptional Items	-	-	-	-	-	-
5	Profit/ (loss) before tax (3-4)	185.57	170.33	121.78	355.90	226.43	435.58
6	Tax expense:						
	I) Current Tax	42.80	39.85	19.83	82.65	47.01	102.64
	II) Deferred Tax	8.81	7.54	13.92	16.35	15.83	24.91
	<b>Total Tax (I+II)</b>	<b>51.61</b>	<b>47.39</b>	<b>33.75</b>	<b>99.00</b>	<b>62.84</b>	<b>127.54</b>
7	Profit (Loss) for the period after Tax (5-6)	<b>133.96</b>	<b>122.94</b>	<b>88.03</b>	<b>256.90</b>	<b>163.59</b>	<b>308.04</b>
8	<b>Other comprehensive income (Net of Tax)</b>						
A.	Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	Re-measurement gain on defined benefit plans	-	-	-	-	-	9.61
B	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	<b>Total Other Comprehensive Income for the period (A+B)(net of taxes)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>9.61</b>
9	<b>Total Comprehensive Income for the period (7+8)</b>	<b>133.96</b>	<b>122.94</b>	<b>88.03</b>	<b>256.90</b>	<b>163.59</b>	<b>317.65</b>
10	Paid-up equity share capital (Face Value of Rs. 10/- each)	826.37	826.37	773.87	826.37	773.87	826.37
11	Other Equity	-	-	-	-	-	2,339.54
12	Earnings per equity share (face value of Rs.10/- each) not annualised						
	(1) Basic	1.62	1.49	1.14	3.11	2.11	3.73
	(2) Diluted	1.62	1.49	1.14	3.11	2.11	3.73

**Notes:**

- The above standalone unaudited financial results for the quarter and six months ended 30.09.2019 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective meeting held on Nov. 13, 2019. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results.
- Previous period figures are regrouped/reclassified in line with the current period.
- The Company has only one reportable business segment.
- The standalone unaudited financial results have been prepared in accordance with the Indian Accounting Standards ("Ind AS") specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").

For and on behalf of Board of Directors  
for **TITAN BIOTECH LIMITED**

  
**NARESH KUMAR SINGLA**  
Managing Director  
DIN-00027448

Place : Delhi  
Dated : 13.11.2019



**TITAN BIOTECH LIMITED**

Regd. Office :- A-902 A RITCO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Fax No. +91-11-47619811 Email : hrd@titanbiotechltd.com www.titanbiotechltd.com CIN : L74999RJ1992PLC013387

**STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30TH SEPT. 2019**  
(Rs. IN LAKHS) except for EPS

Sr. No.	PARTICULARS	STANDALONE					
		QUARTER ENDED			SIX MONTHS ENDED		YEAR ENDED
		30.09.2019	30.06.2019	30.09.2018	30.09.2019	30.09.2018	31.03.2019
		UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
1	Total Income from Operations (Net)	1,624.78	1,755.38	1,508.30	3,380.16	2,969.74	5,889.18
2	Net Profit/(Loss) for the period (before tax, exceptional and/or extraordinary items)	185.57	170.33	121.78	355.90	226.43	435.58
3	Net Profit/(Loss) for the period before tax (after exceptional and/or extraordinary items)	185.57	170.33	121.78	355.90	226.43	435.58
4	Net Profit/(Loss) for the period after tax (after exceptional and/or extraordinary items)	133.96	122.94	88.03	256.90	163.59	308.04
5	Total comprehensive income for the period (comprising Profit/(Loss) for the period (after tax) and Other Comprehensive income (after tax) (refer note 3)	133.96	122.94	88.03	256.90	163.59	317.65
6	Paid-up Equity Share Capital (Face value of Rs. 10/- per share)	826.37	826.37	773.87	826.37	773.87	826.37
7	Other Equity excluding Revaluation Reserves as per the balance sheet	-	-	-	-	-	2,339.54
8	Earning Per Share (of INR 10/- each)						
	(a) Basic	1.62	1.49	1.14	3.11	2.11	3.73
	(b) Diluted	1.62	1.49	1.14	3.11	2.11	3.73

**NOTES :**

- The above is an extract of the detailed format of standalone unaudited Financial Results for the quarter and six months ended 30th Sept, 2019 filed with the BSE Limited Under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Standalone Unaudited Financial Results for the said quarter and six months ended 30th Sept, 2019 are available on the website of BSE Limited at www.bseindia.com and on company website at www.titanbiotechltd.com.
- The above standalone unaudited financial results for the quarter and six months ended 30.09.2019 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective meeting held on Nov. 13, 2019. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results.
- The standalone unaudited financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").

For and on behalf of Board of Directors  
for **TITAN BIOTECH LIMITED**

  
**NARESH KUMAR SINGLA**

Managing Director

DIN-00027448

Place : Delhi

Dated : 13.11.2019



**TITAN BIOTECH LIMITED**  
**Standalone Balance Sheet as at 30 Sept, 2019**

(Rs. in Lakhs.)

Particulars	As at	
	30/09/2019 Unaudited	31/03/2019 Audited
<b>I ASSETS</b>		
<b>1. Non-Current Assets</b>		
a. Property, Plant and Equipment	2,613.38	2,580.99
b. Capital Work-in-Progress	-	-
c. Intangible assets	4.11	9.42
d. Financial Assets	-	-
(i) Investments	127.49	127.49
(ii) Other Financial Assets	60.87	56.40
<b>Total Non-current assets</b>	<b>2,805.85</b>	<b>2,774.31</b>
<b>2. Current Assets</b>		
a. Inventories	2,036.58	1,996.00
b. Financial Assets	-	-
(i) Trade receivables	776.83	783.66
(ii) Cash and cash equivalents	76.63	158.80
(iii) Bank balances other than (ii) above	16.13	16.13
c. Current Tax Assets (Net)	-	-
d. Other Current Assets	164.95	252.67
<b>Total Current assets</b>	<b>3,071.12</b>	<b>3,207.26</b>
<b>TOTAL ASSETS</b>	<b>5,876.97</b>	<b>5,981.56</b>
<b>II. EQUITY AND LIABILITIES</b>		
<b>A Equity</b>		
a. Equity Share Capital	826.37	826.37
b. Other Equity	2,596.44	2,339.54
<b>TOTAL EQUITY</b>	<b>3,422.81</b>	<b>3,165.91</b>
<b>B Liabilities</b>		
<b>1. Non-Current Liabilities</b>		
a. Financial Liabilities		
(i) Borrowings	905.67	1,201.60
b. Deferred tax liabilities (Net)	118.35	101.99
c. Provisions	95.89	95.89
<b>Total Non-Current Liabilities</b>	<b>1,119.90</b>	<b>1,399.49</b>
<b>2. Current Liabilities</b>		
a. Financial Liabilities		
(i) Borrowings	846.96	883.77
(ii) Trade payables	264.28	206.39
(iii) Other financial liabilities	185.22	246.92
b. Other current liabilities	15.67	71.09
c. Current Tax Liabilities (Net)	22.13	7.99
<b>Total Current Liabilities</b>	<b>1,334.26</b>	<b>1,416.17</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>5,876.97</b>	<b>5,981.56</b>

For Titan Biotech Limited

[Naresh Kumar Singla]

Managing Director

DIN-00027448

Place : Delhi

Date : 13.11.2019



**TITAN BIOTECH LIMITED**

Regd. Office :- A-902 A, RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Fax No. +91-11-47619811 Email : hrd@titanbiotechltd.com www.titanbiotechltd.com CIN : L74999RJ1992PLC013387

**STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30TH SEPT, 2019**

(Rs. IN LAKHS) except for EPS

Sr. No	PARTICULARS	CONSOLIDATED					
		QUARTER ENDED			SIX MONTHS ENDED		YEAR ENDED
		30.09.2019	30.06.2019	30.09.2018	30.09.2019	30.09.2018	31.03.2019
		UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
1	<b>INCOME</b>						
	Revenue from operations	1,850.62	2,209.37	1,701.45	4,059.99	3,273.36	6,490.80
	Other Income	40.49	11.16	12.92	51.65	31.01	68.65
	<b>Total Income</b>	<b>1,891.11</b>	<b>2,220.54</b>	<b>1,714.37</b>	<b>4,111.64</b>	<b>3,304.37</b>	<b>6,559.45</b>
2	<b>EXPENSES</b>						
	Cost of Materials Consumed	934.50	1,169.82	826.31	2,104.32	1,686.10	3,654.97
	Changes in Inventories of Finished Goods, Stock-in-Trade and Work-in-Progress	6.09	10.82	(31.21)	16.91	(110.09)	(384.89)
	Employee Benefit Expenses	302.46	277.72	280.78	580.18	501.45	1,026.55
	Finance Costs	55.80	60.08	60.66	115.88	110.48	228.99
	Depreciation and Amortization Expenses	44.97	44.39	28.73	89.36	88.73	171.16
	Other Expenses	346.82	297.87	374.03	644.69	720.54	1,308.27
	<b>Total Expenses</b>	<b>1,690.64</b>	<b>1,860.70</b>	<b>1,539.30</b>	<b>3,551.34</b>	<b>2,997.21</b>	<b>6,005.05</b>
3	Profit/(loss) before exceptional items and tax (1-2)	200.46	359.84	175.07	560.30	307.16	554.41
4	Exceptional Items	-	-	-	-	-	-
5	Profit/ (loss) before tax (3-4)	200.46	359.84	175.07	560.30	307.16	554.41
6	Tax expense:						
	I) Current Tax	46.61	92.21	33.43	138.82	67.53	137.47
	II) Earlier year taxes	-	-	-	-	-	0.12
	III) Deferred Tax	6.36	7.90	14.20	14.26	16.33	25.58
	<b>Total Tax (I+II)</b>	<b>52.97</b>	<b>100.11</b>	<b>47.63</b>	<b>153.08</b>	<b>83.86</b>	<b>163.18</b>
7	Profit (Loss) for the period after Tax (5-6)	<b>147.49</b>	<b>259.73</b>	<b>127.44</b>	<b>407.22</b>	<b>223.30</b>	<b>391.23</b>
8	<b>other comprehensive income (Net of Tax)</b>						
A	Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	Re-measurement gain on defined benefit plans	-	-	-	-	-	9.78
	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
B	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	<b>Total Other Comprehensive Income for the period (A+B)(net of taxes)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>9.78</b>
9	<b>Total Comprehensive Income for the period (7+8)</b>	<b>147.49</b>	<b>259.73</b>	<b>127.44</b>	<b>407.22</b>	<b>223.30</b>	<b>401.01</b>
10	<b>Net profit attributable to:</b>						
	Owners of the holding company	142.46	195.61	108.97	338.06	195.31	352.23
	Non-controlling interest	5.04	64.12	18.47	69.16	27.99	39.00
11	<b>Other comprehensive income attributable to :</b>						
	Owners of the holding company	-	-	-	-	-	9.70
	Non-controlling interest	-	-	-	-	-	0.08
12	<b>Total Comprehensive Income attributable to (10+11)</b>						
	Owners of the holding company	142.46	195.61	108.97	338.06	195.31	361.93
	Non-controlling interest	5.04	64.12	18.47	69.16	27.99	39.08
13	Paid-up equity share capital (Face Value of Rs. 10/- each)	826.37	826.37	773.87	826.37	773.87	826.37
14	Other Equity	-	-	-	-	-	2,391.26
15	Earnings per equity share (face value of Rs.10/- each) not annualised						
	(1) Basic	1.72	2.37	1.41	4.09	2.52	4.26
	(2) Diluted	1.72	2.37	1.41	4.09	2.52	4.26

**Notes:**

- The above consolidated unaudited financial results for the quarter and six months ended 30.09.2019 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective meeting held on Nov 13, 2019. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results.
- The consolidated unaudited financial results for the quarter and six months ended 30th Sept, 2019 include the results of following:-  
Subsidiary Company - Peptech Biosciences Limited
- Previous period figures are regrouped/reclassified in line with the current period.
- The Company has only one reportable business segment.
- The consolidated unaudited financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").

For and on behalf of Board of Directors  
for TITAN BIOTECH LIMITED

**NARESH KUMAR SINGLA**

Managing Director

DIN-00027448

Place : Delhi

Dated : 13.11.2019



**TITAN BIOTECH LIMITED**

Regd. Office :- A-902 A RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Fax No. +91-11-47619811 Email : hrd@titanbiotechltd.com www.titanbiotechltd.com CIN : L74999RJ1992PLC013387

**STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30TH SEPT, 2019**

(Rs. IN LAKHS) except for EPS

Sl. No.	PARTICULARS	CONSOLIDATED					
		QUARTER ENDED			SIX MONTHS ENDED		YEAR ENDED
		30.09.2019	30.06.2019	30.09.2018	30.09.2019	30.09.2018	31.03.2019
		UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
1	Total Income from Operations (Net)	1,891.11	2,220.54	1,714.37	4,111.64	3,304.37	6,559.45
2	Net Profit/(Loss) for the period (before tax, exceptional and/or extraordinary items)	200.46	359.84	175.07	560.30	307.16	554.41
3	Net Profit/(Loss) for the period before tax (after exceptional and/or extraordinary items)	200.46	359.84	175.07	560.30	307.16	554.41
4	Net Profit/(Loss) for the period after tax (after exceptional and/or extraordinary items)	147.49	259.73	127.44	407.22	223.30	391.23
5	Total comprehensive income for the period (comprising Profit/(Loss) for the period (after tax) and Other Comprehensive income (after tax) (refer note 3)	317.65	259.73	127.44	317.65	317.65	401.01
6	Paid-up Equity Share Capital (Face value of Rs. 10/- per share)	826.37	826.37	773.87	826.37	773.87	826.37
7	Other Equity excluding Revaluation Reserves as per the balance sheet	-	-	-	-	-	2,391.26
8	Earning Per Share (of INR 10/- each)						
	(a) Basic	1.72	2.37	1.41	4.09	2.52	4.26
	(b) Diluted	1.72	2.37	1.41	4.09	2.52	4.26

**NOTES :**

- The above is an extract of the detailed format of consolidated unaudited Financial Results for the quarter and six months ended 30th Sept, 2019 filed with the BSE Limited Under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the consolidated unaudited Financial Results for the said quarter and six months ended 30th Sept, 2019 are available on the website of BSE Limited at [www.bseindia.com](http://www.bseindia.com) and on company website at [www.titanbiotechltd.com](http://www.titanbiotechltd.com).
- The above consolidated unaudited financial results for the quarter and six months ended 30.09.2019 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective meeting held on Nov 13, 2019. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results.
- The consolidated unaudited financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").

For and on behalf of Board of Directors  
for TITAN BIOTECH LIMITED

**NARESH KUMAR SINGLA**

Managing Director

DIN-00027448

Place : Delhi

Dated : 13.11.2019



**TITAN BIOTECH LIMITED**  
**Consolidated Balance Sheet as at 30th Sept, 2019**

(Rs. in Lakhs.)

Particulars	As at	
	30/09/2019 Unaudited	31/03/2019 Audited
<b>I ASSETS</b>		
<b>1. Non-Current Assets</b>		
a. Property, Plant and Equipment	2,927.42	2,892.41
b. Capital Work-in-Progress	6.13	-
c. Intangible assets	4.11	9.42
d. Financial Assets	-	-
(i) Other Financial Assets	61.60	57.04
e. Other Non Current Assets	0.45	0.60
<b>Total Non-current assets</b>	<b>2,999.71</b>	<b>2,959.46</b>
<b>2. Current Assets</b>		
a. Inventories	2,275.18	2,113.32
b. Financial Assets	-	-
(i) Trade receivables	1,248.78	924.31
(ii) Cash and cash equivalents	95.24	187.48
(iii) Bank balances other than (ii) above	16.13	16.13
c. Current Tax Assets (Net)	-	-
d. Other Current Assets	178.32	272.27
<b>Total Current assets</b>	<b>3,813.65</b>	<b>3,513.51</b>
<b>TOTAL ASSETS</b>	<b>6,813.36</b>	<b>6,472.97</b>
<b>II. EQUITY AND LIABILITIES</b>		
<b>A Equity</b>		
a. Equity Share Capital	826.37	826.37
b. Other Equity	2,729.62	2,391.26
c. Non Controlling Interest	227.00	158.15
<b>TOTAL EQUITY</b>	<b>3,782.99</b>	<b>3,375.78</b>
<b>B Liabilities</b>		
<b>1. Non-Current Liabilities</b>		
a. Financial Liabilities		
(i) Borrowings	1,247.99	1,316.60
b. Deferred tax liabilities (Net)	119.52	105.26
c. Provisions	97.58	97.58
<b>Total Non-Current Liabilities</b>	<b>1,465.09</b>	<b>1,519.45</b>
<b>2. Current Liabilities</b>		
a. Financial Liabilities		
(i) Borrowings	976.49	967.62
(ii) Trade payables	326.16	214.49
(iii) Other Financial Liabilities	181.74	280.96
b. Other current liabilities	25.20	96.86
c. Current Tax Liabilities (Net)	55.68	17.82
<b>Total Current Liabilities</b>	<b>1,565.28</b>	<b>1,577.75</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>6,813.36</b>	<b>6,472.97</b>

For Titan Biotech Limited

[Naresh Kumar Singla]

Managing Director

DIN-00027448

Place : Delhi

Date : 13.11.2019